File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/JTO.0b013e3181b9c77e
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Title | Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer |
---|---|
Authors | |
Issue Date | 2009 |
Publisher | Lippincott Williams & Wilkins. |
Citation | The 13th World Conference on Lung Cancer (WCLC 2009), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9 suppl. 1, p. S719, abstract no. P1.263 How to Cite? |
Abstract | BACKGROUND: Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. PURPOSE: To evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. METHOD: Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as first-line treatment and subsequent salvage treatment with erlotinib. RESULTS: A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 11 (52.4%) patients with erlotinib. There was an association between the disease control with gefitinib and erlotinib (p=0.016). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. CONCLUSION: For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib. |
Persistent Identifier | http://hdl.handle.net/10722/133873 |
ISSN | 2023 Impact Factor: 21.0 2023 SCImago Journal Rankings: 7.879 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, MKY | - |
dc.contributor.author | Lo, AI | - |
dc.contributor.author | Lam, WK | - |
dc.contributor.author | Lam, B | - |
dc.contributor.author | Ip, MSM | - |
dc.contributor.author | Ho, JCM | - |
dc.date.accessioned | 2011-06-02T02:10:06Z | - |
dc.date.available | 2011-06-02T02:10:06Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | The 13th World Conference on Lung Cancer (WCLC 2009), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9 suppl. 1, p. S719, abstract no. P1.263 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | http://hdl.handle.net/10722/133873 | - |
dc.description.abstract | BACKGROUND: Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. PURPOSE: To evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. METHOD: Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as first-line treatment and subsequent salvage treatment with erlotinib. RESULTS: A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 11 (52.4%) patients with erlotinib. There was an association between the disease control with gefitinib and erlotinib (p=0.016). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. CONCLUSION: For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins. | - |
dc.relation.ispartof | Journal of Thoracic Oncology | - |
dc.rights | This is a non-final version of an article published in final form in (provide complete journal citation) | - |
dc.title | Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1556-0864&volume=4&issue=9, suppl. 1&spage=S719, abstract no. P1.263&epage=&date=2009&atitle=Erlotinib+as+salvage+treatment+after+failure+to+first-line+gefitinib+in+non-small+cell+lung+cancer | - |
dc.identifier.email | Wong, MKY: drmwong@HKUCC-COM.hku.hk | - |
dc.identifier.email | Lam, WK: lamwk@hku.hk | - |
dc.identifier.email | Lam, B: lambing@HKUCC.hku.hk | - |
dc.identifier.email | Ip, MSM: msmip@hku.hk | - |
dc.identifier.email | Ho, JCM: jhocm@hku.hk | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1097/JTO.0b013e3181b9c77e | - |
dc.identifier.hkuros | 172607 | - |
dc.identifier.volume | 4 | - |
dc.identifier.issue | 9 suppl. 1 | - |
dc.identifier.spage | S719, abstract no. P1.263 | - |
dc.identifier.epage | S719, abstract no. P1.263 | - |
dc.description.other | The 13th World Conference on Lung Cancer (WCLC), San Francisco, CA., 31 July-4 August 2009. In Journal of Thoracic Oncology, 2009, v. 4 n. 9, suppl. 1, p. S719, abstract no. P1.263 | - |
dc.identifier.issnl | 1556-0864 | - |